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The effects of angiotensin 
receptor neprilysin inhibition by 
sacubitril/valsartan on adipose 
tissue transcriptome and protein 
expression in obese hypertensive 
patients
R. Stinkens  1, B. W. van der Kolk1, J. Jordan2,3, T. Jax4, S. Engeli2, T. Heise4, J. W. Jocken1,  
M. May  5, C. Schindler5, B. Havekes1,6, N. Schaper6,7, D. Albrecht8, S. Kaiser8, N. Hartmann8, 
M. Letzkus8, T. H. Langenickel8, G. H. Goossens1 & E. E. Blaak1
Increased activation of the renin-angiotensin system is involved in the onset and progression of 
cardiometabolic diseases, while natriuretic peptides (NP) may exert protective effects. We have 
recently demonstrated that sacubitril/valsartan (LCZ696), a first-in-class angiotensin receptor neprilysin 
inhibitor, which blocks the angiotensin II type-1 receptor and augments natriuretic peptide levels, 
improved peripheral insulin sensitivity in obese hypertensive patients. Here, we investigated the 
effects of sacubitril/valsartan (400 mg QD) treatment for 8 weeks on the abdominal subcutaneous 
adipose tissue (AT) phenotype compared to the metabolically neutral comparator amlodipine (10 mg 
QD) in 70 obese hypertensive patients. Abdominal subcutaneous AT biopsies were collected before and 
after intervention to determine the AT transcriptome and expression of proteins involved in lipolysis, 
NP signaling and mitochondrial oxidative metabolism. Both sacubitril/valsartan and amlodipine 
treatment did not significantly induce AT transcriptional changes in pathways related to lipolysis, 
NP signaling and oxidative metabolism. Furthermore, protein expression of adipose triglyceride 
lipase (ATGL) (Ptime*group = 0.195), hormone-sensitive lipase (HSL) (Ptime*group = 0.458), HSL-ser660 
phosphorylation (Ptime*group = 0.340), NP receptor-A (NPRA) (Ptime*group = 0.829) and OXPHOS complexes 
(Ptime*group = 0.964) remained unchanged. In conclusion, sacubitril/valsartan treatment for 8 weeks did 
not alter the abdominal subcutaneous AT transcriptome and expression of proteins involved in lipolysis, 
NP signaling and oxidative metabolism in obese hypertensive patients.
Obesity is strongly associated with cardiometabolic risk factors1, which is reflected by an increased risk for arte-
rial hypertension, heart failure and type 2 diabetes2. An impaired adipose tissue function and excessive fat mass 
in obesity represent key factors in the development of insulin resistance and related chronic diseases, including 
cardiovascular disease and type 2 diabetes3. Evidence suggests that impaired insulin sensitivity in obesity might 
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be related to an altered renin-angiotensin system (RAS) and natriuretic peptide (NP) signaling in adipose tis-
sue. Blockade of the RAS using angiotensin-converting enzyme (ACE) inhibitors or angiotensin type-1 receptor 
blockers (ARB) has been shown to improve insulin sensitivity and beta-cell function4 and reduces the incidence 
of type 2 diabetes5 as reviewed elsewhere6. However, results are not consistent7. In addition, NPs are positively 
associated with insulin sensitivity and low atrial natriuretic peptide (ANP) concentrations are associated with an 
increased risk of developing arterial hypertension and type 2 diabetes8. In accordance, neprilysin (NEP), which 
is involved in the degradation and inactivation of NP, is linked to insulin resistance, increased blood pressure 
and impaired lipid metabolism9. Therefore, combined RAS blockade and NEP inhibition might have synergistic 
beneficial effects on blood pressure and peripheral insulin sensitivity. We recently demonstrated that combined 
ARB and NEP inhibition, using sacubitril/valsartan (LCZ696), improved peripheral insulin sensitivity following 8 
weeks of treatment compared to amlodipine (AMLO) in obese hypertensive patients10. However, the mechanisms 
underlying these beneficial effects remain to be established.
Evidence suggests that both the RAS and ANP affect adipose tissue metabolism, thereby determining insulin 
sensitivity6,11. It has been shown that valsartan (ARB) reduced adipocyte size, increased adipose tissue blood flow 
and decreased gene expression of angiogenesis, adipogenesis and macrophage infiltration markers12, which may 
have contributed to the valsartan-induced increased insulin sensitivity4. Furthermore, angiotensin II inhibited 
lipolysis in vitro in mature human adipocytes13, although conflicting findings on adipose tissue lipolysis in vivo 
in humans have been reported14,15. ANP has been shown to increase adipose tissue lipid mobilization and oxida-
tion11 and we and others have recently demonstrated that ANP-mediated lipolysis is impaired in subcutaneous 
mature adipocytes from obese men with and without type 2 diabetes16,17.
Therefore, it is hypothesized that ARB and NEP inhibition with sacubitril/valsartan may affect adipose tissue 
function, thereby contributing to the observed improved peripheral insulin sensitivity in obese individuals10. The 
present study investigated the effects of sacubitril/valsartan compared to amlodipine treatment for 8 weeks on 
the abdominal subcutaneous adipose tissue transcriptome and protein expression profiles in obese hypertensive 
individuals.
Methods
Study design. Ninety-eight obese hypertensive patients participated in a multicenter, randomized, dou-
ble-blind, parallel-group study to investigate the effects of sacubitril/valsartan (400 mg QD) compared with 
amlodipine (10 mg QD) treatment for 8 weeks. A detailed description of the study design, key inclusion and 
exclusion criteria of the patients and the primary results of this study have been described elsewhere10 (clinicaltri-
als.gov - NCT01631864, registered June 27, 2012). Briefly, the study included a screening period of up to 4 weeks, 
followed by a 4-week washout period and an 8-week randomized, double-blind and double-dummy treatment 
phase. Patients receiving antihypertensive medications at the time of screening discontinued the therapy during 
the washout period. During the treatment period, patients were randomized to receive either sacubitril/valsartan 
(400 mg QD) or amlodipine (10 mg QD) along with a matching placebo for 8 weeks. Patients were stratified into 
four groups based on the baseline Homeostasis Model Assessment of Insulin Resistance and statin use.
All patients gave written informed consent before participation and for the use of their adipose tissue biopsies 
in the current research investigation. The study was reviewed and approved by the Institutional Review Boards 
(IRB) of the Maastricht University Medical Center+ and at each participating centers’ IRBs. The study was per-
formed in accordance with the Declaration of Helsinki.
Before and after treatment, abdominal subcutaneous adipose tissue biopsies were collected by needle aspi-
ration under local anesthesia after an overnight fast. Subjects showing a treatment-induced increase in adipose 
tissue lipolysis in vivo (increase from baseline microdialysis glycerol concentration) following sacubitril/valsartan 
and subjects showing an unchanged lipolysis in vivo (change from baseline microdialysis glycerol concentration 
between −30 and +10 μmol/L) after amlodipine treatment10 were included in the following analyses. We deter-
mined adipose tissue gene expression profiles using microarray analysis in a subgroup of 70 patients who had a 
RNA Integrity Number (RIN) ≥5.0, as described in detail below. Also, in a subgroup (n = 12–13), we determined 
the expression of proteins involved in the lipolytic pathway, the natriuretic peptide signaling pathway and mito-
chondrial oxidative phosphorylation.
Adipose tissue transcriptomics. After extraction, the integrity of abdominal subcutaneous adipose tissue 
total RNA was determined using the sample RNA Integrity Number (RIN), generated using an Agilent 2100 
Bioanalyzer (Agilent Technologies Inc., Foster City, CA, USA). RIN values <5.0 indicated high level of sample 
total RNA degradation and were excluded from analyses18. Biopsies of 70 patients (n sacubitril/valsartan = 36, n 
amlodipine = 34) were eligible for transcriptional analyses (RIN ≥5.0).
Transcriptional data were generated using Affymetrix HG-U133plus2.0 oligonucleotide microarrays 
(Affymetrix Inc., Santa Clara, CA, USA) and the microarray files were pre-processed using the Robust Multi-array 
Average algorithm (RMA). The Chip Definition File (CDF) used for the RMA procedure corresponded to the 
public domain Michigan University Entrez CDF version 17.0. Transcripts showing median expression higher 
than 6 (log2-value) were combined and considered for statistical analyses.
All transcriptional analyses were performed in R: a language and environment for statistical computing 
(v.3.2.2 - R Foundation for Statistical Computing, Vienna, Austria. http://www.R-project.org). To identify and 
correct for potential sources of genomic data variation, the R/Bioconductor packages PVCA and ComBat (cur-
rently implemented as a function in the SVA R package) were used. To identify transcriptional changes induced 
by treatment, linear models followed by contrasts were defined and implemented using the LIMMA package 
(v.3.26.8). For this study, the threshold for statistical change significance was setup at nominal P-value ≤ 0.05. 
Nominal P-values were adjusted for multiple testing using the Bonferroni correction as well as the false dis-
covery rate (FDR). A total of 8319 transcripts (out of assessed 18898 transcripts per microarray) fulfilled the 
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expression level filtering criteria. The Bonferroni adjusted threshold was therefore defined as P < 6.01·10−6. The 
size of longitudinal treatment-induced transcriptional changes was expressed as Ratio Change from baseline 
[RC; (post-treatment level)·(pre-treatment level)−1)]. Thresholds for minimum relevant treatment-induced 
effects were defined as 0.66 ≥ RC ≥ 1.50 (i.e. RC range equivalent to absolute fold changes ≥1.5). The longitudinal 
treatment-induced effects on specific transcripts encoding for selected adipokines and gene products linked to 
the following biological processes: i) lipolysis, ii) fatty acid oxidation, iii) mitochondrial biogenesis, were also 
explored regardless of whether they surpassed or not the expression level filtering criteria stated above.
Adipose tissue protein expression. A detailed description of the analysis can be found in the 
Supplementary Material. Briefly, abdominal subcutaneous adipose tissue was ground to a fine powder under 
liquid nitrogen and homogenized in RIPA buffer. The homogenate was lysed, vortexed and centrifuged and the 
supernatant was collected and stored at −80 °C. The protein concentration was determined by the Bradford-based 
protein assay. Next, solubilized proteins (15 µg) were separated on a precast gel and transferred onto a nitrocellu-
lose membrane and quantitative Western Blot analysis was performed to determine the levels of proteins involved 
in the lipolytic pathway (adipose triglyceride lipase (ATGL), hormone sensitive lipase (HSL) and HSL serine 660 
phosphorylation), the natriuretic peptide signaling pathway (natriuretic peptide receptor A (NPRA)) and mito-
chondrial oxidative phosphorylation (OXPHOS).
Protein expression data are expressed as mean ± S.E.M. All variables were checked for normal distribution 
by Shapiro-Wilk test and variables were Ln-transformed to satisfy conditions of normality (HSL, HSL S660 
phosphorylation, NPRA and OXPHOS). Data was analyzed using two-way repeated measures ANOVA, with 
time (pre, post) and treatment (sacubitril/valsartan, amlodipine) as factors. Bonferroni post-hoc correction was 
applied when a significant time*treatment interaction was found. Calculations were performed using SPSS v.21 
for Mac OSX (IBM, Chicago, IL, USA) and P ≤ 0.05 was considered statistically significant.
The datasets generated and/or analyzed during the current study can be made available by reasonable request 
to the corresponding author.
Results
Subject characteristics. Characteristics of patients contributing to the present study are shown in Table 1. 
Importantly, the two groups were well matched and there were no major differences in clinical characteristics 
between groups.
Transcriptomics. Although transcriptional assessments revealed 1443 longitudinally treatment-modulated 
transcripts (nominal P < 0.05), none of them fulfilled both thresholds for Bonferroni adjusted P-value and 
minimum treatment-induced RC effect. A set of selected transcripts is shown in Supplementary Table S1. 
Moreover, gene expression levels of transcripts involved in lipolysis, NP signaling, oxidative metabolism and 
adipokines (Fig. 1) showed no significant treatment-induced changes (defined based on the two thresholds stated 
above). Specifically, gene expression of ATGL (PNPLA2), MGL (MGLL), lipoprotein lipase (LPL), perilipin-1 
(PLIN1) and fatty acid binding protein 4 (FABP4) was not significantly altered by sacubitril/valsartan treatment 
(Fig. 1). In addition, gene expression of natriuretic peptide receptors (NPR1, NPR3), adipokines (adiponectin 
Transcriptomic analyses
Sacubitril/valsartan n = 36 Amlodipine n = 34 Total n = 70
Parameter Baseline Post intervention Baseline Post intervention Baseline Post intervention
Age (yrs.) 52.4 (8.56) — 51.6 (9.21) — 52.0 (8.83) —
Gender (n)
  Male 28 — 25 — 53 —
  Female 8 — 9 — 17 —
  Weight (kg) 100 (18.2) 101 (19.0) 104 (15.8) 105 (16.4) 102 (17.1) 103 (17.8)
  BMI (kg·(m2)−1) 32.4 (4.77) 32.6 (5.03) 33.6 (4.59) 33.8 (4.96) 33.0 (4.69) 33.2 (5.00)
Mean sitting SBP (mm Hg) 143.2 (13.26) 122.5 (9.97) 138.8 (11.61) 125.5 (12.28) 141.0 (12.60) 124.0 (11.17)
Mean sitting DBP (mm Hg) 89.6 (7.79) 81.9 (8.40) 90.4 (5.87) 83.4 (6.19) 90.0 (6.89) 82.6 (7.40)
Protein expression analyses
Sacubitril/valsartan n = 15 Amlodipine n = 12 Total n = 27
Parameter Baseline Post intervention Baseline Post intervention Baseline Post intervention
Age (yrs.) 53.6 (6.92) — 54.9 (7.04) — 54.2 (6.87) —
Gender (n)
  Male 13 — 8 — 21 —
  Female 2 — 4 — 6 —
  Weight (kg) 108 (19.2) 109 (19.8) 102 (14.4) 103 (15.1) 105 (17.1) 106 (17.8)
  BMI (kg·(m2)−1) 34.3 (5.89) 34.7 (6.05) 33.1 (3.93) 33.6 (4.18) 33.8 (5.06) 34.2 (5.24)
Mean sitting SBP (mm Hg) 147.2 (10.62) 127.9 (11.72) 137.8 (12.59) 125.9 (13.37) 143.0 (12.27) 127.0 (12.27)
Mean sitting DBP (mm Hg) 92.0 (6.10) 68.3 (10.38) 87.5 (5.63) 66.7 (8.81) 90.0 (6.22) 67.6 (9.57)
Table 1. Clinical characteristics of patients involved in transcriptomic and protein expression analyses. Data 
are expressed as mean (SD).
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(ADIPOQ), leptin (LEP)) and oxidative metabolism markers (peroxisome proliferator-activated receptor 
gamma co-activator-related 1 (PPRC1), peroxisome proliferator-activated receptor gamma co-activator 1 alpha 
(PPARGC1A), nuclear respiratory factor 1 (NRF1), acyl-coenzyme A oxidase 1 (ACOX1) and uncoupling pro-
tein 2 (UCP2)) were not significantly affected (Fig. 1). The FDR-adjusted P-values revealed only 28 transcripts 
in the sacubitril/valsartan group, in which only 1 transcript (Cholesteryl Ester Transfer Protein (CETP), Entrez 
Gene: 1071) fulfilled both the adjusted P-value and the absolute fold change criteria. In the amlodipine group, 15 
transcripts showed an FDR-adjusted P-value ≤ 0.05 of which only 1 transcript (CETP) fulfilled both the adjusted 
P-value and the absolute fold change criteria. CETP was upregulated by both treatments.
Protein expression. Sacubitril/valsartan (LCZ696) treatment did not significantly change pro-
tein expression of ATGL (LCZ696: 1.00 ± 0.21 vs. 0.85 ± 0.19 AU; AMLO: 1.00 ± 0.26 vs. 1.36 ± 0.30 AU; 
Ptime = 0.583, Ptime*treatment = 0.195; Fig. 2A), HSL (LCZ696: 1.00 ± 0.23 vs. 1.38 ± 0.24 AU; AMLO: 1.00 ± 0.26 vs. 
1.00 ± 0.18 AU; Ptime = 0.141, Ptime*treatment = 0.458; Fig. 2B), HSL serine 660 phosphorylation (LCZ696: 1.00 ± 0.16 
vs. 1.04 ± 0.14 AU; AMLO: 1.00 ± 0.25 vs. 0.71 ± 0.19 AU; Ptime = 0.551, Ptime*treatment = 0.340; Fig. 2C) or NPRA 
(LCZ696: 1.00 ± 0.24 vs. 0.99 ± 0.29 AU; AMLO: 1.00 ± 0.36 vs. 0.96 ± 0.30 AU; Ptime = 0.775, Ptime*treatment = 0.829; 
Fig. 2D). Furthermore, total OXPHOS protein expression (LCZ696: 1.00 ± 0.22 vs. 1.76 ± 0.48 AU; AMLO: 
1.00 ± 0.15 vs. 1.74 ± 0.50 AU; Ptime = 0.125, Ptime*treatment = 0.964; Fig. 2E) remained unchanged following treat-
ment. More specifically, OXPHOS complexes I-V were not affected (data not shown).
Discussion
Here, we investigated the effects of sacubitril/valsartan versus amlodipine treatment for 8 weeks on the abdominal 
subcutaneous adipose tissue transcriptome and protein expression in obese hypertensive patients. We demon-
strated that sacubitril/valsartan treatment did not significantly alter adipose tissue gene and protein expression of 
factors related to lipolysis, natriuretic peptide signaling and oxidative metabolism.
We recently demonstrated that in obese hypertensive patients sacubitril/valsartan treatment, which pro-
vides simultaneous ARB blockade and NEP inhibition, significantly increased peripheral insulin sensitivity10. 
Furthermore, sacubitril/valsartan slightly but significantly increased abdominal subcutaneous adipose tissue 
lipolysis, although no changes in whole-body lipolysis were observed10. Therefore, we hypothesized that RAS 
blockade and NEP inhibition has synergistic beneficial effects on abdominal subcutaneous adipose tissue metab-
olism and might underlie the observed improvement in insulin sensitivity. We showed that the abdominal adipose 
tissue phenotype was not significantly affected by 8 weeks of sacubitril/valsartan treatment in obese hypertensive 
Figure 1. Targeted assessment of selected treatment-induced transcriptional changes in abdominal 
subcutaneous adipose tissue. The heatmap plot shows per patient longitudinal treatment-induced gene 
expression changes [defined as log2(post treatment expression) - log2(pre-treatment expression)] for selected 
transcripts related to natriuretic peptide signaling, lipolytic pathway, oxidative pathway and adipokines in 
abdominal subcutaneous adipose tissue (n = 70 patients; grouped per treatment arm). Color in the heatmap 
reflects transcript change from baseline per subject. Blue: downregulated transcripts; yellow: upregulated 
transcripts. The adjacent table depicts the corresponding transcript ratio change from baseline (RC) and P-value 
per treatment arm.
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patients. First, sacubitril/valsartan treatment did not elicit significant transcriptional changes in abdominal sub-
cutaneous adipose tissue. In particular, no treatment-induced changes in expression of genes involved in lipol-
ysis, the NP signaling pathway and mitochondrial oxidative pathway were detected. Secondly, the expression of 
proteins involved in these pathways, as well as post-translational modification of HSL, remained unchanged after 
the intervention.
Evidence suggests that both the RAS and NP system may affect adipose tissue metabolism, thereby contribut-
ing to improved insulin sensitivity6,11. It has previously been shown that angiotensin II decreased adipose tissue 
lipolysis in vivo in humans14,19,20 and in human isolated adipocytes13, which seems to be mediated via the angi-
otensin II type-1 receptor. However, increased adipose tissue lipolysis has also been reported15. In accordance 
with our results, long-term ARB treatment with valsartan improved insulin sensitivity in subjects with impaired 
glucose metabolism4, but adipose tissue gene and protein expression of several lipolytic enzymes remained 
unchanged12.
Several studies have shown that ANP promotes adipose tissue lipid mobilization and oxidation in healthy 
individuals11 via cGMP-mediated phosphorylation of HSL21,22. Furthermore, ANP induced mitochondrial 
Figure 2. Protein expression in abdominal subcutaneous adipose tissue. Expression of proteins involved in 
the lipolytic pathway (ATGL, n = 12, (A); HSL, n = 13, (B); HSL serine 660 phosphorylation, n = 13, (C), the 
natriuretic peptide signaling pathway (NPR-A, n = 12, D) and mitochondrial oxidative metabolism (total 
OXPHOS, n = 13, E) expressed as fold change relative to baseline for each treatment arm (Sacubitril/valsartan: 
LCZ696 or Amlodipine: AMLO). Data are expressed as mean ± S.E.M. White bars: baseline values; black 
bars: post-treatment values. Representative (cropped) western blots of which membranes were probed with 
antibodies directed against total ATGL, total HSL, phosphorylated HSL (p-HSL) on Ser660 and NPRA (F) and 
uncropped western blots of OXPHOS protein expressions (G).
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biogenesis and uncoupling in human adipocytes from healthy, non-diabetic women23. Here, we did not find 
significant changes in gene and protein expression of markers involved in lipolysis, phosphorylation of HSL and 
mitochondrial oxidative metabolism, which may be explained by reduced ANP-mediated signaling in the study 
population. Indeed, an impaired ANP-mediated lipolysis has recently been described in situ in subcutaneous adi-
pose tissue and in vitro in subcutaneous adipocytes from obese individuals16,17. Moreover, it has been shown that 
NPRC (NP clearance receptor) is increased in adipose tissue of obese hypertensive patients compared to lean and 
normotensive individuals24, together with increased NEP expression in obesity9. These data suggest reduced NP 
signaling and increased NP clearance in adipose tissue in obesity. This may explain the unaltered subcutaneous 
adipose tissue metabolic phenotype following sacubitril/valsartan treatment in the present study.
In general, the observed relative changes in gene expression were very modest, revealing only minor, poten-
tially not physiologically relevant, changes in gene expression. Due to conservative multiple testing correction 
(Bonferroni correction), relevant treatment-induced changes in gene expression may have been missed. However, 
even when a less stringent method was used (FDR-adjusted data), only minor changes in gene expression were 
found.
Although we did not observe significant alterations in subcutaneous adipose tissue gene and protein expres-
sion of factors related to lipolysis, natriuretic peptide signaling and oxidative metabolism after 8 weeks of treat-
ment with sacubitril/valsartan or amlodipine in obese hypertensive subjects, it remains to be investigated whether 
changes would occur in other adipose tissue depots, such as the visceral adipose tissue. Moreover, it would have 
been interesting to compare the effects of sacubitril/valsartan to placebo. However, since obese hypertensive 
patients are in need of anti-hypertensive treatment, we decided to use the metabolically neutral blood pressure 
lowering agent amlodipine as a comparator in this study instead.
Conclusion
The present study demonstrated that simultaneous RAS blockade and NEP inhibition following sacubitril/val-
sartan treatment for 8 weeks did not significantly alter the adipose tissue metabolic phenotype in obese hyper-
tensive patients. More specifically, abdominal subcutaneous adipose tissue gene and protein expression of factors 
involved in lipolysis, natriuretic peptide signaling and mitochondrial oxidative metabolism remained unchanged. 
Therefore, alterations in the adipose tissue metabolic phenotype do not seem to contribute to the improved 
peripheral insulin sensitivity following 8 weeks of sacubitril/valsartan treatment10.
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